ABSTRACT
PURPOSE: Recent studies have suggested that machine learning (ML) could be used to predict venous thromboembolism (VTE) in cancer patients with high accuracy.
METHODS: We aimed to evaluate the performance of ML in predicting VTE events in patients with cancer. PubMed, Web of Science, and EMBASE to identify studies were searched.
RESULTS: Seven studies involving 12,249 patients with cancer were included. The combined results of the different ML models demonstrated good accuracy in the prediction of VTE. In the training set, the global pooled sensitivity was 0.87, the global pooled specificity was 0.87, and the AUC was 0.91, and in the test set 0.65, 0.84, and 0.80, respectively.
CONCLUSION: The prediction ML models showed good performance to predict VTE. External validation to determine the result's reproducibility is necessary.
PMID:37616550 | DOI:10.1200/CCI.23.00060
21:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
21:26
In reply to this message
PubMed articles on: Cancer & VTE/PE
No evidence for a genetic causal effect of breast cancer on venous thromboembolism: a mendelian randomization study
J Thromb Thrombolysis. 2023 Aug 24. doi: 10.1007/s11239-023-02871-1. Online ahead of print.
ABSTRACT
Active cancer is known to contribute to venous thromboembolism (VTE), but the cause-and-effect association of breast cancer on VTE is not yet clear. In order to investigate the possible causal relationships, we used a Mendelian randomization analysis. Data for generically predicted breast cancer were identified based on the BCAC consortium. A meta-analysis of genome-wide association study (GWAS) comprising 1,500,861 participants for VTE as well as data from the FinnGen study for VTE, DVT and PE was used for the causal-effect estimation. Our primary method was inverse-variance weighted (IVW), and our supplementary methods included weighted median and MR-Egger. We also carried out sensitivity analysis for the study. No evidence of causal-effect was detected of overall breast cancer on VTE in both the GWAS meta-analysis (OR=1.01, 95%CI:0.98-1.04, p = 0.495) and the FinnGen consortium (OR=1.00,95%CI:0.96-1.04, p = 0.945). In addition, the presence of ER-positive or ER-negative disease did not significantly influence the incidence of VTE and its subtypes. In conclusion, no genetic cause-and-effect of breast cancer on VTE risk was detected in the large MR analysis.
PMID:37615800 | DOI:10.1007/s11239-023-02871-1
21:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
21:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
21:26
PubMed articles on: Cancer & VTE/PE
Physicians' assessment of complications after gynecological surgery in Sweden: The GYNCOM survey
Acta Obstet Gynecol Scand. 2023 Aug 23. doi: 10.1111/aogs.14661. Online ahead of print.
ABSTRACT
INTRODUCTION: Complications after gynecological surgery in Sweden are registered in the well-established Swedish National Quality Register of Gynecological Surgery, GynOp. The aim of this study was to analyze interrater reliability in assessing complications according to the methods in GynOp, and to explore physicians' perceptions of registering complications.
MATERIAL AND METHODS: A digital survey was sent to gynecologists and residents in gynecology in Sweden. Participating clinics were recruited through the Swedish network for national clinical studies in Obstetrics and Gynecology, SNAKS. Twenty fictional cases, intended to represent normal postoperative course, failure to cure, and varying degrees of complications, were developed by the research group. The clinical scenarios included abdominal and laparoscopic surgery of the uterus and adnexa, vaginal hysterectomies, as well as hysteroscopy. The respondents graded each case on the presence of a complication (yes/no). Type of complication, severity, and what action the complication required according to Clavien-Dindo was registered if a complication was acknowledged, according to the method in GynOp. Interrater reliability and the opinions of the respondents were presented descriptively. More than 80% of respondents making the same assessment was considered as agreement.
RESULTS: The response rate was 41%, with 104 responding physicians from 16 gynecological clinics. Type and severity of complication was considered relevant to register by 88% and 89% of respondents, respectively. Agreement on whether the case described a complication was >80% in 85% (17/20) of cases and agreement using the Clavien-Dindo classification was >90% in 80% (16/20) of cases. There was high agreement in assessments of classically severe complications, such as pulmonary embolism and ureteral damage, in both presence of complication and severity, as well as Clavien-Dindo (>90% for all methods). Cases with agreement <80%
CONCLUSIONS: This study provides validation for the methods used to register complications after gynecological surgery according to the GynOp register, including the use of Clavien-Dindo in gynecology. However, the results indicate a need to define what should be considered symptoms inherent to each type of surgery.
PMID:37614120 | DOI:10.1111/aogs.14661
21:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
21:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
C
23:35
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
In reply to this message
PubMed articles on: Cardio-Oncology
Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma
Front Immunol. 2023 Aug 15;14:1243980. doi: 10.3389/fimmu.2023.1243980. eCollection 2023.
ABSTRACT
BACKGROUND: Immune checkpoint inhibitor (ICI)-associated cardiotoxicity is a relatively uncommon immune-related adverse effects (irAEs) with a high mortality rate. There are few recommendations for the replacement of different immune checkpoint inhibitors in domestic and international reports.
CASE PRESENTATION: We report a case of a patient with squamous non-small cell lung carcinoma (squamous NSCLC) who developed cardiotoxicity after being treated with a programmed death-1 (PD-1) inhibitor and then changed to a PD-L1 inhibitor to continue the treatment. A significant benefit was observed after four cycles of immunotherapy, and no further cardiotoxicity occurred after the treatment was started.
CONCLUSION: This case demonstrates that myocardial damage induced by tislelizumab (PD-1 inhibitor) can be improved after switching to sugemalimab (PD-L1 inhibitor) and that antitumor immunotherapy is effective. This result may have important implications for optimizing immunotherapy management regimens in cancer patients.
PMID:37649479 | PMC:PMC10465174 | DOI:10.3389/fimmu.2023.1243980
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
In reply to this message
PubMed articles on: Cardio-Oncology
Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry
ESC Heart Fail. 2023 Aug 30. doi: 10.1002/ehf2.14506. Online ahead of print.
ABSTRACT
AIMS: Hospital admission during nighttime and off hours may affect the outcome of patients with various cardiovascular conditions due to suboptimal resources and personnel availability, but data for acute heart failure remain controversial. Therefore, we studied outcomes of acute heart failure patients according to their time of admission from the global International Registry to assess medical practice with lOngitudinal obseRvation for Treatment of Heart Failure.
METHODS AND RESULTS: Overall, 18 553 acute heart failure patients were divided according to time of admission into 'morning' (7:00-14:59), 'evening' (15:00-22:59), and 'night' (23:00-06:59) shift groups. Patients were also dichotomized to admission during 'working hours' (9:00-16:59 during standard working days) and 'non-working hours' (any other time). Clinical characteristics, treatments, and outcomes were compared across groups. The hospital length of stay was longer for morning (odds ratio: 1.08; 95% confidence interval: 1.06-1.10, P < 0.001) and evening shift (odds ratio: 1.10; 95% confidence interval: 1.07-1.12, P < 0.001) as compared with night shift. The length of stay was also longer for working vs. non-working hours (odds ratio: 1.03; 95% confidence interval: 1.02-1.05, P < 0.001). There were no significant differences in in-hospital mortality among the groups. Admission during working hours, compared with non-working hours, was associated with significantly lower mortality at 1 year (hazard ratio: 0.88; 95% confidence interval: 0.80-0.96, P = 0.003).
CONCLUSIONS: Acute heart failure patients admitted during the night shift and non-working hours had shorter length of stay but similar in-hospital mortality. However, patients admitted during non-working hours were at a higher risk for 1 year mortality. These findings may have implications for the health policies and heart failure trials.
PMID:37649316 | DOI:10.1002/ehf2.14506
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:35
PubMed articles on: Cardio-Oncology
Heterotopia of salivary gland tissue in the pancreas
23:35
PubMed articles on: Cardio-Oncology
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer
23:35
PubMed articles on: Cardio-Oncology
Radiation therapy in the thoracic region: Radio-induced cardiovascular disease, cardiac delineation and sparing, cardiac dose constraints, and cardiac implantable electronic devices
23:35
PubMed articles on: Cardio-Oncology
Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions
23:35
PubMed articles on: Cardio-Oncology
Role of echocardiography in patients treated with immune checkpoints inhibitors
23:36
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:36
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:36
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
23:36
In reply to this message
PubMed articles on: Cardio-Oncology
Risk of Cancer After Diagnosis of Cardiovascular Disease
JACC CardioOncol. 2023 Apr 11;5(4):431-440. doi: 10.1016/j.jaccao.2023.01.010. eCollection 2023 Aug.
ABSTRACT
BACKGROUND: Cardiovascular disease (CVD) and cancer share several risk factors. Although preclinical models show that various types of CVD can accelerate cancer progression, clinical studies have not determined the impact of atherosclerosis on cancer risk.
OBJECTIVES: The objective of this study was to determine whether CVD, especially atherosclerotic CVD, is independently associated with incident cancer.
METHODS: Using IBM MarketScan claims data from over 130 million individuals, 27 million cancer-free subjects with a minimum of 36 months of follow-up data were identified. Individuals were stratified by presence or absence of CVD, time-varying analysis with multivariable adjustment for cardiovascular risk factors was performed, and cumulative risk of cancer was calculated. Additional analyses were performed according to CVD type (atherosclerotic vs nonatherosclerotic) and cancer subtype.
RESULTS: Among 27,195,088 individuals, those with CVD were 13% more likely to develop cancer than those without CVD (HR: 1.13; 95% CI: 1.12-1.13). Results were more pronounced for individuals with atherosclerotic CVD (aCVD), who had a higher risk of cancer than those without CVD (HR: 1.20; 95% CI: 1.19-1.21). aCVD also conferred a higher risk of cancer compared with those with nonatherosclerotic CVD (HR: 1.11; 95% CI: 1.11-1.12). Cancer subtype analyses showed specific associations of aCVD with several malignancies, including lung, bladder, liver, colon, and other hematologic cancers.
CONCLUSIONS: Individuals with CVD have an increased risk of developing cancer compared with those without CVD. This association may be driven in part by the relationship of atherosclerosis with specific cancer subtypes, which persists after controlling for conventional risk factors.
PMID:37614573 | PMC:PMC10443115 | DOI:10.1016/j.jaccao.2023.01.010
23:36
In reply to this message
PubMed articles on: Cardio-Oncology
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors: In Search of the Echocardiography Holy Grail
JACC CardioOncol. 2023 Aug 15;5(4):486-488. doi: 10.1016/j.jaccao.2023.07.003. eCollection 2023 Aug.
ABSTRACT
PMID:37614572 | PMC:PMC10443194 | DOI:10.1016/j.jaccao.2023.07.003
23:36
In reply to this message
PubMed articles on: Cardio-Oncology
Prostate Cancer and Cardiovascular Risk Factors
JACC CardioOncol. 2023 Aug 15;5(4):551. doi: 10.1016/j.jaccao.2023.03.016. eCollection 2023 Aug.
NO ABSTRACT
PMID:37614571 | PMC:PMC10443193 | DOI:10.1016/j.jaccao.2023.03.016
1 September 2023
C
01:26
Cardiotoxicity News
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
In reply to this message
PubMed articles on: Cancer & VTE/PE
The unfolded protein response links ER stress to cancer-associated thrombosis
JCI Insight. 2023 Aug 31:e170148. doi: 10.1172/jci.insight.170148. Online ahead of print.
ABSTRACT
Thrombosis is a common complication of advanced cancer. Yet the cellular mechanisms linking malignancy to thrombosis are poorly understood. The unfolded protein response (UPR) is an ER stress response associated with advanced cancers. A proteomic evaluation of plasmas from gastric and non-small cell lung cancer patients who were monitored prospectively for venous thromboembolism demonstrated increased levels of UPR-related markers in plasmas of patients who developed clots compared to those who did not. Release of procoagulant activity into supernatants of gastric, lung, and pancreatic cancer cells was enhanced by UPR induction and blocked by antagonists of the UPR receptors IRE1α or PERK. Release of extracellular vesicles bearing tissue factor (EVTF) from pancreatic cancer cells was inhibited by siRNA-mediated knockdown of IRE1α/XBP1 or PERK pathways. Induction of UPR did not increase TF synthesis, but rather stimulated localization of TF to the cell surface. UPR-induced TF delivery to EVTFs was inhibited by Arf1 knockdown or GBF1 antagonism, confirming the role of vesicular trafficking. Our findings show that UPR activation results in increased vesicular trafficking leading to release of prothrombotic EVTFs, thus providing a mechanistic link between ER stress and cancer-associated thrombosis.
PMID:37651191 | DOI:10.1172/jci.insight.170148
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
In reply to this message
PubMed articles on: Cancer & VTE/PE
Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study
J Intern Med. 2023 Aug 28. doi: 10.1111/joim.13712. Online ahead of print.
ABSTRACT
BACKGROUND: Safety data for different anticoagulant medications in venous thromboembolism (VTE) are scarce, in particular for extended treatment.
OBJECTIVES: To compare major bleeding rates depending on the choice of anticoagulation during initial (first 6 months) and extended treatment (6 months up to 5 years).
METHODS: A nationwide register-based study including cancer-free patients with a first-time VTE between 2014 and 2020. Cox proportional hazards models were used to compare bleeding rates.
RESULTS: We included 6558 patients on warfarin, 18,196 on rivaroxaban, and 19,498 on apixaban. At 6 months, 4750 (72.4%) remained on warfarin, 11,366 (62.5%) on rivaroxaban, and 11,940 (61.2%) on apixaban. During initial treatment, major bleeding rates were 3.86 (95% CI 3.14-4.58), 2.93 (2.55-3.31), and 1.95 (1.65-2.25) per 100 patient-years for warfarin, rivaroxaban, and apixaban, respectively, yielding adjusted hazard ratios (aHRs) of 0.89 (95% CI 0.71-1.12) for rivaroxaban versus warfarin, 0.55 (0.43-0.71) for apixaban versus warfarin, and 0.62 (0.50-0.76) for apixaban versus rivaroxaban. During extended treatment, major bleeding rates were 1.55 (1.19-1.91), 1.05 (0.85-1.26), and 0.96 (0.78-1.15) per 100 patient-years for warfarin, rivaroxaban, and apixaban, respectively, with aHRs of 0.72 (0.53-0.99) for rivaroxaban versus warfarin, 0.60 (0.44-0.82) for apixaban versus warfarin, and 0.85 (0.64-1.12) for apixaban versus rivaroxaban. Previous bleeding and increasing age were risk factors for bleeding both during initial and extended treatment.
CONCLUSION: Apixaban had a lower bleeding risk than warfarin or rivaroxaban during initial treatment. During extended treatment, bleeding risk was similar for apixaban and rivaroxaban, and higher with warfarin.
PMID:37641391 | DOI:10.1111/joim.13712
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
Photo
Not included, change data exporting settings to download.
1200×1200, 39.0 KB
01:26
In reply to this message
PubMed articles on: Cancer & VTE/PE
Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management
Diagnostics (Basel). 2023 Aug 17;13(16):2698. doi: 10.3390/diagnostics13162698. ABSTRACTWe aimed to overview the most recent data on sternal metastases from a multidisciplinary approach (diagnosis strategies, outcome, and histological reports). This narrative review based on a PubMed search (between January 2020 and 22 July 2023) using key words such as "sternal", "manubrium", and "metastasis" within the title and/or abstract only included original papers that specifically addressed secondary sternal spreading of cancer in adults, for a total of 48 original articles (14 studies and 34 single case reports). A prior unpublished case in point is also introduced (percutaneous incisional biopsy was used to address a 10 cm sternal tumour upon first admission on an apparently healthy male). The studies (n = 14) may be classified into one of three groups: studies addressing the incidence of bone metastases (including sternum) amid different primary cancers, such as prostate cancer (N = 122 with bone metastases, 83% of them with chest wall metastases), head and neck cancers (N = 3620, 0.8% with bone metastases, and 10.34% of this subgroup with sternum involvement); and glioblastoma (N = 92 with bone metastases, 37% of them with non-vertebral metastases, including the sternum); assessment cohorts, including breast cancer (N = 410; accuracy and sensitivity of PET/CT vs. bone scintigraphy is superior with concern to sternum spreading) and bone metastases of unknown origin (N = 83, including a subgroup with sternum metastases; some features of PET/CT help the differentiation with multiple myeloma); and cohorts with various therapeutic approaches, such as palliative arterial embolization (N = 10), thymic neuroendocrine neoplasia (1/5 detected with sternum metastases), survival rates for sternum metastases vs. non-sternum chest wall involvement (N = 87), oligo-metastatic (sternal) breast cancer (3 studies, N = 16 for all of them), oligo-metastatic head and neck cancer (N = 81), conformal radiotherapy (N = 24,215, including an analysis on sternum spreading), and EBRT followed by MR-HIFU (N = 6). Core data coming from the isolated case reports (N = 34) showed a female to male ratio of 1.6; the females' ages were between 34 and 80 (mean of 57.28) and the males' ages varied between 33 and 79 (average of 58.78) years. The originating tumour profile revealed that the most frequent types were mammary (N = 8, all females) and thyroid (N = 9, both women and men), followed by bladder (N = 3), lung (N = 2), and kidney (N = 2). There was also one case for each of the following: adenoid cystic carcinoma of the jaw, malignant melanoma, caecum MiNEN, a brain and an extracranial meningioma, tongue carcinoma, cholangiocarcinoma, osteosarcoma, and hepatocellular carcinoma. To our knowledge, this is the most complex and the largest analysis of prior published data within the time frame of our methods. These data open up new perspectives of this intricate, dynamic, and challenging domain of sternum metastases. Awareness is a mandatory factor since the patients may have a complex multidisciplinary medical and/or surgical background or they are admitted for the first time with this condition; thus, the convolute puzzle will start from this newly detected sternal lump. Abbreviations: N = number of patients; n = number of studies; PET/CT = positron emission tomography/computed tomography; EVRT = external beam radiotherapy; MR-HIFU = magnetic resonance-guided high-intensity focused ultrasound; MiNEN = mixed neuroendocrine-non-neuroendocrine tumour.
PMID:37627957 | PMC:PMC10453928 | DOI:10.3390/diagnostics13162698
01:26
In reply to this message
PubMed articles on: Cancer & VTE/PE
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
J Cancer Res Clin Oncol. 2023 Aug 25. doi: 10.1007/s00432-023-05321-w. Online ahead of print.
No comments:
Post a Comment
اكتب تعليق حول الموضوع